Compare Johnson Controls International PLC (JCI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs McKesson Corporation — how do they compare? Johnson Controls International PLC trades at $157.44 (market cap $93.28B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and Johnson Controls International PLC pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and McKesson Corporation for 74 Days on average.
| JCI | MCK | |
|---|---|---|
Market Cap | $93.28B | $108.46B |
Volume | 2,786,476 | 712,607 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $995.69 |
52-Week Low | $105.55 | $725.17 |
Typical Hold Time | 65 Days | 74 Days |
Enterprise Value | $102.12B | $115.00B |
Dividend Yield | 1.04% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
